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Background   Patients with a hip fracture have a high mortality; 
however, it is not clear how large the loss of life-years is over an 
extended observation period.
Subjects and methods   This was a cohort study involving all 
patients in Denmark who suffered a hip fracture between 1977 
and 2001 (n = 169,145). The survival rate for these patients was 
compared to that for age- and sex-matched subjects without a hip 
fracture (n = 524,010).
Results   There was a substantial degree of excess mortality, 
with a pronounced variation in age and sex. The absolute number 
of life-years lost compared to age-matched subjects without a hip 
fracture was larger in younger subjects than in older subjects 
(men aged 51–60 years lived 7.5 years less on average while men 
over 80 years of age lived 3 years less). Expressed as a percentage, 
however, older subjects had the largest relative loss of expected 
remaining years of life. Men ≤ 50 years of age lost 18% of their 
expected remaining years of life, as opposed to men > 80 years of 
age who lost as much as 58% of their expected remaining years of 
life. In women, the trend was similar but less pronounced (27% 
loss in women ≤ 50 years of age vs. 38% in women > 80 years of 
age).
Interpretation   A large proportion of the estimated remaining 
life is lost after a hip fracture, even in younger patients. Preven-
tion may save life years, although not all of the years lost after a 
hip fracture may be due to the hip fracture per se.

Patients with a hip fracture have an added risk of dying (Jacob-
sen et al. 1992), especially within the first year after the frac-
ture (Vestergaard et al. 2007b).
Although there have been a number of studies on survival 
after a hip fracture (Miller 1978, Jensen and Tondevold 1979, 
Dahl 1980, Kreutzfeldt et al. 1984, Holmberg et al. 1986, 
Magaziner et al. 1989, Parker and Anand 1991, Jacobsen et 
al. 1992, Cooper et al. 1993, Schroder et al. 1993, Pitto 1994, 
Poor et al. 1995, Magaziner et al. 1997, Vestergaard et al. 
2007b), little is known about the absolute risk of death in frac-
ture cases compared to controls, about the contribution of age 
and sex to the change in absolute risk of death following a hip 
fracture, and about how large a proportion of the remaining 
years is lost. Although there have been no randomized con-
trolled trials on prevention of deaths through primary preven-
tion of hip fractures, observational studies have indicated that 
a large proportion of the excess mortality after the hip frac-
ture may perhaps be related to the hip fracture per se, as there 
was additional mortality even after adjustment for pre-fracture 
morbidity and co-morbidity (Vestergaard et al. 2007b). 
Recent randomized controlled trials on intervention with intra-
venous bisphosphonates after a hip fracture have also shown 
that an increase in survival may be obtained with bisphospho-
nates (Lyles et al. 2007). After 2 years, the survival seen in hip 
fracture patients was approximately 75% in women and 55% in 
men as compared to an expected survival rate of approximately 
85% in both sexes (Jacobsen et al. 1992). If some age and sex 
strata are especially prone to large losses of expected remaining 
lifetime, prevention may be especially targeted towards these 
groups. Most studies have limited their observations to the first 
few years after the hip fracture, i.e. little is known about the 
long-term effects of a hip fracture on survival (Parker et al. 
1991, Jacobsen et al. 1992, Cooper et al. 1993, Poor et al. 1995, 
Magaziner et al. 1997, Vestergaard et al. 2007b).
Two research groups have reported long-term survival after 
a hip fracture. The first group (Elmerson et al. 1988) reported 
a high 10-year mortality rate, especially in patients who were 
discharged to an institution. The second group (Holmberg et 
al. 1986) also reported high 6-year mortality, especially in 
patients discharged to an institution.
Adjustment for co-morbidity in previous studies has had 
little effect on the excess mortality (Vestergaard et al. 2007b). 
Absolute rather than multiply-adjusted estimates of lost life-
years would thus provide an easily accessible estimate of loss 
of life after a hip fracture. We assessed the absolute mortality 
after a hip fracture and compared it to that in subjects with 
no hip fracture, stratified by age and sex, and determined the 
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lost in patients who sustained a hip fracture over an extended 
observation period.
Subjects and methods
In Denmark, the widespread existence of registers covering 
contacts with the health sector offers a good opportunity to 
carry out studies on the occurrence of fractures (Frank 2000). 
The Danish National Health Service provides tax-supported 
healthcare for all inhabitants, allowing free access to general 
practitioners  and  hospitals.  Using  the  unique  10-digit  civil 
registry number that is assigned to all Danish citizens, a com-
plete picture of hospital contact can be established for each 
individual, and linkage of data between population-based reg-
istries can be obtained. 
In Denmark, the National Hospital Discharge Register covers 
all contacts with hospitals, either on an inpatient or on an out-
patient basis (Andersen et al. 1999). The register was founded 
in 1977, but outpatient records were incorporated completely 
starting from 1995. The files of this register include informa-
tion on the civil registry number of the patient, the date of dis-
charge, and the diagnoses at discharge (both principal diagno-
ses and additional diagnoses)—which were assigned only by 
the physician at the time of discharge according to the Danish 
version of the International Classification of Diseases, eighth 
revision (ICD-8), until the end of 1993, and to the Danish ver-
sion of the International Classification of Diseases, tenth revi-
sion (ICD-10). The register has nationwide coverage of public 
hospitals with an almost 100% completeness of recording and 
a high precision of diagnoses (Andersen et al. 1999), espe-
cially of fracture diagnoses (Mosbech et al. 1995). This cohort 
study was performed using the whole of the Danish popula-
tion, which was approximately 5.3 million individuals during 
the study period.
The study was subject to control by the National Board of 
Health and the Danish Data Protection Agency.
Study design
The study was designed as a classical historic cohort study 
where exposure was presence of a hip fracture or not, and out-
come was mortality. Several designs may be chosen for com-
parison of survival in patients and referents. In this study, we 
chose a matched cohort design to ensure the presence of refer-
ents in all age groups, even the oldest (in other study designs, 
few older subjects may be chosen if a random sample of the 
population is drawn). The design was also chosen to allow 
direct comparison of subjects with and without a hip fracture 
to allow individual-based assessment of differences in survival 
based on a large section of the population.
Identification of hip fracture patients
Data on all patients with a fracture of the hip (ICD8 codes 
820.00 and 820.01, ICD10 codes S72.0 and S72.1) in Den-
mark  in  the  25-year  period  between  January  1,  1977  and 
December 31, 2001 were retrieved from the National Hospital 
Register (Andersen et al. 1999).
Identification of subjects with no hip fracture
Using the Civil Registration System, which as of 1968 has 
had electronic records on all changes in vital status, including 
change of address and date of death for the entire Danish pop-
ulation, we randomly selected 3 subjects with no hip fracture 
(controls) for each hip fracture patient, matched by sex and 
year of birth. The controls were selected using the incidence-
density sampling technique (Wacholder et al. 1992), that is, 
the controls had to be alive and at risk of fracture at the time 
the hip fracture in the patient corresponding to the controls 
was diagnosed.
The controls were not required to have been hip or femur 
fracture cases in the period from 1977 through 2001. Controls 
who later sustained a hip fracture were censored at the time of 
their later hip fracture.
Information on vital status
We retrieved information of migrations and date of death from 
the Central Person Register (via the National Bureau of Statis-
tics). Patients or controls who emigrated were censored on the 
date of emigration using individual data on observation time. 
Statistics
Data from the different registers were merged at the National 
Bureau of Statistics, and for each subject the 10-digit civil reg-
istry number was substituted by a unique case number; thus, 
as investigators we had no access to personally identifiable 
information. Statistics Denmark holds a key to translate the 
scrambled identification numbers into the original personal 
identification  numbers,  thus  allowing  identification  of  the 
individual patients. Mean (SD) was used for descriptive sta-
tistics. Survival was analyzed using actuarial methodology.
One-year intervals were used for the calculations. The number 
of life years was calculated as the area under the curve for 
up to 25 years of observation. The loss of life years was then 
taken as the difference between the area under the curve for 
the hip fracture patients and the controls. Comparisons of sur-
vival were based on log-rank test. Analyses were performed 
using Stata version 8.1 (StataCorp LP, College Station, TX) 
and SPSS version 15.0 (SPSS Inc., Chicago, IL), both in the 
Unix version. 
Results
Data from 169,145 hip fracture patients and 524,010 subjects 
with no hip fracture were used in the study. They had a mean 
age of 77 (64–90) years, and 28% were men, similar between 
cases and controls (Table 1). Although there were more co-
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limited in absolute terms (e.g. was the difference between prev-
alence of any liver disease statistically significant, although in 
percent the difference ranged from 1% to < 1%). 
Figure 1 show actuarial survival after a hip fracture, strati-
fied by age and sex. In all scenarios, patients with a hip frac-
ture had a higher mortality than the age- and sex-matched sub-
jects with no hip fracture (2p < 0.01 by log-rank test, and also 
by Cox proportional hazard regression). The survival curves 
diverged for more than 1 year following a hip fracture, indi-
cating that there was even excess mortality many years after 
a hip fracture. In patients aged ≤ 50 years with hip fractures, 
men had a better survival rate than women (2p < 0.01 by log-
rank test) (Figure 1a), whereas in all other age strata women 
had a better survival rate than men (2p < 0.01 by log-rank test) 
(Figures 1b–e).
With increasing age, the survival of the subjects without a 
hip fracture decreased and more subjects died during the first 
20 years of observation (Figure 1). However, the survival of 
the hip fracture patients also decreased. The differences in 
terms of absolute survival were large, especially within the 
than 50% in men of > 60 years with no hip fracture). A large 
proportion of the excess mortality took place within the first 
year following the hip fracture. In contrast to previous studies, 
our study allows estimation of the percentage of lost remain-
ing lifetime and analysis of long-term survival. The study does 
not allow calculation of the percentage of the years of life lost 
that were due to the hip fracture, and thus possibly preventable. 
Many other factors apart from the hip fracture—such as alco-
holism and smoking—may also contribute to the loss of life 
years, and this should be addressed in detail in future studies.
The expected survival in our study was close to that observed 
in one previous study: 85% in the study by Jacobsen et al. 
(1992) as compared to 86% (95% CI: 85–87) in our study. 
However, the survival rate seen in our study—49% (95 CI: 
48–50) in men and 65% (95 CI: 64–66) in women aged ≥ 65 
years—was somewhat lower than that observed in the study 
by Jacobsen et al. (1992) (55% in men vs. 75% in women). 
The differences may be linked to differences in co-morbidity 
levels and the fact that we did not exclude pathological frac-
tures linked to cancer metastases.
Table 1. Baseline characteristics of the fracture patients and the control subjects with no hip 
fracture
    Matched controls
   Hip fracture patients    with no hip fracture     p-value
Variable  (n = 169,145)     (n = 524,010) 
Sex
  Male    46,073 (28%)  144,695 (28%)   –a
  Female   122,422 (72%)    379,315 (72%)
Age, mean (SD)    77.0 (13.0)    77.0 (13.0)    –a
Died during follow-up
  Yes    121,953 (72%)    352,636 (67%)    < 0.01b
Charlson index
  0 (no co-morbidity)    92,571 (55%)  311,823 (60%)  < 0.01b
  1–2    57,579 (34%)  150,835 (29%)
  3–4    13,838 (8%)    39,104 (8%)
  ≥ 5        5,157 (3%)     22,248 (4%)  
Co-morbidity before the hip fracture
   Cancer    20,120 (12%)    75,177 (14%)  < 0.01b
   Previous acute myocardial infarction      9,827 (6%)    43,153 (8%)  < 0.01b
  Arteriosclerosis      6,370 (4%)    16,302 (3%)  < 0.01b
   Chronic obstructive pulmonary disease    12,761 (8%)    30,480 (6%)  < 0.01b
   Cerebrovascular disease    16,641 (10%)    39,077 (8%)  < 0.01b
   Dementia      7,402 (4%)    11,225 (2%)  < 0.01b
   Diabetes     11,179 (7%)    29,154 (6%)  < 0.01b
   Heart failure     13,258 (8%)    44,360 (9%)  < 0.01b
   Any liver disease       2,371 (1%)      3,367 (< 1%)  < 0.01b
   Any kidney disease    11,468 (7%)      24,132 (5%)  < 0.01b  
  Alcoholism        5,423 (3%)        4,678 (1%)    < 0.01b
Income in DKR (SD)      86,804 (127,447)      96,162 (135,847)    < 0.01c
Civil status      < 0.01b
  Widowed  78,178 (46%)  263,455 (50%)
  Divorced  14,426 (9%)    36,815 (7%)
  Married  55,561 (33%)  169,097 (32%)
  Never married  20,973 (12%)    54,580 (10%)
  Other           17 (< 0.1%)             63 (< 0.1%)  
a No comparisons as data were matched.
b χ2 test.
c t-test for 2 samples.
first year following the hip fracture.
Confounding within age strata did 
not  affect  the  results.  Limiting  the 
analyses to patients who had survived 
for more than 1 year after the hip frac-
ture  (i.e.  elimination  of  the  initially 
high mortality rate) had essentially no 
effect on the results (data not shown).
Table 2 summarizes the number of 
life years lost during the observation 
period of up to 25 years. Whereas the 
largest  loss  in  absolute  numbers  of 
years of life was seen in the youngest 
age  strata,  the  largest  percentage  of 
expected remaining years of life was 
lost in the older age strata (up to 58% 
(56–60)  of  the  expected  remaining 
lifetime in men > 80 years of age).
Alcoholism  was  associated  with 
a  loss  of  expected  remaining  years. 
Non-alcoholics had a mean rest life-
time of 5.0 (0.4) years, or a mean of 
2.6 (0.4) years lost, equivalent to 34% 
(6)% of the expected remaining life. 
Discussion
In  this  large-scale  population-based 
cohort study, we have shown a large 
loss of remaining lifetime in patients 
with a hip fracture (around one-third 
of that expected in women > 50 years 
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At 1 year following a hip fracture, Magaziner et al. (1989) 
reported an expected survival rate of 95% in women and 92% 
in  men  as  compared  to  the  observed 
survival  rate  of  85%  in  women  and 
73% in men. In our study, the actual 
survival rate was 74% (95 CI: 73–75) 
in women and 60% (95 CI: 59–61) in 
men, i.e. somewhat lower than reported 
by Magaziner et al. (1989). The differ-
ences may be related to the fact that the 
population studied by Magaziner et al. 
(1989) was a selected population from 
one university hospital in an urban set-
ting.
None  of  the  previous  studies  have 
provided follow-up beyond a few years 
after the hip fracture (Parker and Ananad 
1991, Jacobsen et al. 1992, Cooper et 
al. 1993, Poor et al. 1995, Magaziner et 
al. 1997, Vestergaard et al. 2007b). Our 
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Figure 1. Actuarial survival in patients with a 
hip fracture and matched controls with no hip 
fracture, all of whom were ≤ 50 years (a), 51–
60 years (b), 61–70 years (c), 71–80 years 
(d) or > 80 years (e) of age at the time of hip 
fracture (or matched dummy date in the case 
of matched controls).
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Table 2. Observed mean remaining years of life for patients with a hip fracture and 
matched controls with no hip fracture within the first 25 years after a hip fracture (or 
corresponding dummy data in the case of controls), years of remaining life lost, and 
percentage loss of expected remaining years of life; mean (1.96 × SEM) 
   Mean remaining years of life     Percentage  
            loss of
      Matched controls      Hip fracture     Years of  remaining
Age  Sex  without a hip fracture    patients  life lost  years of life
≤ 50 years   M   23 (0.2)   19 (0.4)   4.2 (0.4)   18 (2)
  F   24 (0.2)   17 (0.4)   6.3 (0.4)   27 (2)
51–60 years   M   19 (0.2)   12 (0.4)   7.5 (0.4)   39 (2)
  F   21 (0.2)   14 (0.4)   6.5 (0.4)   31 (2)
61–70 years   M   15 (0.2)   7.5 (0.2)   7.5 (0.4)   50 (2)
  F   17 (0.2)   11 (0.2)   5.6 (0.2)   34 (2)
71–80 years   M   9.5 (0.2)   4.2 (0.2)   5.3 (0.2)   56 (2)
  F   11 (0.2)   6.7 (0.2)   3.8 (0.2)   36 (2)
> 80 years   M   5.1 (0.2)   2.1 (0.2)   3.0 (0.2)   58 (4)
  F   5.6 (0.2)   3.5 (0.2)   2.1 (0.2)   38 (4)
study provides long-term data showing that it may take more 
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in the same range as in the background population—this only 
being due to the high mortality in the older age classes. Much 
may thus be gained by prevention.
Previous studies have shown that much of the excess mor-
tality after a hip fracture may be linked to the fracture per se 
(Vestergaard et al. 2007b), and the primary prevention may thus 
be of overriding importance (consisting of measures to pre-
vent the hip fracture from occurring at all). If a hip fracture has 
occurred, prevention of earlier death may prove more difficult 
and involve several factors such as good operative techniques 
(Bannister et al. 1990), experience (Lavernia 1998), anesthet-
ics (Davis et al. 1987), and reduction of the time from fracture 
to surgery (Bottle and Aylin 2006). Furthermore, perioperative 
and postoperative management with blood transfusion (Halm 
et al. 2003), and prevention of deep venous thrombosis and 
pulmonary embolism etc. are also important. As stated above, 
further studies are needed to clarify how large a proportion of 
the years of life lost might be prevented.
The primary preventive measures might consist of measures 
to prevent falls (Becker et al. 2003) and measures to increase 
bone mechanical competence such as medical treatment with 
antiresorptive (Cranney et al. 2001, 2002a, b, c, d) , dual-action 
(O’Donnell et al. 2006), and bone anabolic drugs (Vestergaard 
et al. 2007a), and of measures to prevent the consequences of 
a fall e.g. hip protectors (Mosekilde et al. 2006, Parker et al. 
2005).
The higher survival rate in men with a hip fracture who are 
aged less than 50 years than in corresponding women in this 
age group, which contrasts with the higher survival rate in 
women in all other age strata, may be related to differences in 
fracture patterns. In older women the fractures may be related 
to osteoporosis, whereas in younger individuals accidents may 
be more prominent, and victims of traffic accidents may be 
in a better physical condition than elderly subjects suffering 
from osteoporosis and a number of co-morbidities.
The calculation of life years lost depends on the time span 
of interest, and may be different for an observation period of, 
say, one year and 25 years, as in our study. This must therefore 
be kept in mind when interpreting the data. With a very long 
observation period as in our study, we covered most of the 
expected remaining lifetime in the older age categories, and 
were thus able to estimate the total loss of remaining years 
of life.
When interpreting the survival curves, it must be remem-
bered that although the curves will eventually converge—as 
they are limited to the interval from 1 to 0—the mortality con-
ditioned on the survival time may still be different. Although 
analyses  with  multiple  adjustments  were  performed,  these 
may not have corrected for all factors.
In this study we addressed the number of life years lost after 
a hip fracture. Future studies should determine the proportion 
of life years lost that were in fact attributable to the hip frac-
ture per se. Fractures many years after the hip fracture may not 
be directly attributable to the hip fracture in itself, but may be 
associated with the factors that led to the hip fracture. How-
ever, if these issues can be addressed, both hip fracture and the 
life years lost may be prevented.
The strengths of our study are the large sample size, the 
uniform collection of data, and the long follow-up time. The 
weaknesses are that individual data on body mass index (BMI) 
and smoking were not available.
PV, LR and LM designed the study. PV performed the calculations and drafted 
the first manuscript. All authors prepared the final version of the manuscript.
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